

# Biosimilars Medicines Group "The Facts about Biosimilars"

EAHP conference – satellite symposium  
Vienna, 17 March 2016



EMA has become Medicines for Europe



- Medicines for Europe (formerly EGA) is the voice of the **pharmaceutical companies supplying the largest share of medicines across Europe** and a leading partner for better healthcare for all European patients and healthcare community, representing the generic, biosimilar and value added medicines industries.
- Over **350 manufacturing and research & development sites** across Europe produce your essential medicines, employ over **160.000 people** and invest **up to 17%** of their turnover into **R&D activities**.
- Medicines for Europe members portfolio **covers 80% of therapy areas** and **supplies the majority of all prescribed medicines in Europe**.

# Medicines for Europe Vision 2020

## Our 5 pillars

# Medicines For Europe VISION



PATIENTS



QUALITY



VALUE



SUSTAINABILITY



PARTNERSHIP

# Generic Medicines Group



- The Generic Medicines Group is a sector group of *Medicines for Europe*, representing the generic medicines developers and manufacturers across Europe, which provide high-quality cost-competitive medicines to millions of patients around the world.
- The generic medicines industry has increased access to medicines by over 100% in 7 key therapeutic areas without increasing the overall treatment cost.
- Over 350 manufacturing and research & development sites across Europe produce your essential medicines, employ over 160.000 people and invest up to 17% of their turnover into R&D activities.
- Generic medicines account today for 56% of all dispensed medicines but for only 22% of the pharmaceutical expenditure in Europe. In other words, generic medicines only account for 2-4% of total healthcare costs. Without generic medicines, Europe would have had to pay €100 billion more in 2014 to get the same level of access to treatment as we have today.

# Biosimilar Medicines Group



- The Biosimilar Medicines Group is a sector group of *Medicines for Europe* and represents the **leading companies developing, manufacturing and marketing biosimilar medicines across Europe.**
- With more than **10 years of positive patient treatment experience and 20 products** successfully launched, biosimilar medicines provide today a huge opportunity to deliver significantly improved access to modern therapies for millions of European patients in both chronic and acute care.
- Our members **bring competition to the biological medicines market**, thereby increasing access to highly innovative medical treatments to patients, in Europe and around the world, and supporting the sustainability of the European healthcare systems.

# Value Added Medicines Group



better access. better health.

- The Value Added Medicines Group is a sector group of *Medicines for Europe* which aims at **optimising, rethinking and reinventing medicines based on known molecules** and by bringing untapped innovation to improve care delivery.
- The Value Added Medicines Group adopts a complementary perspective compared to the other *Medicines for Europe* sector groups: by tackling the targeted portion of **patients' needs that remain unmet to this day**, delivering additional improvement to the healthcare community as a whole.
- The Value Added Medicines Group **brings innovative healthcare while preserving healthcare systems sustainability** and access.
- The Value Added Medicines Group will be hosting its first official event next **May 31 in Brussels**, details will be available soon.

## Learn more

[www.medicinesforeurope.com](http://www.medicinesforeurope.com)

[info@medicinesforeurope.com](mailto:info@medicinesforeurope.com)

Twitter

[@medicinesforEU](https://twitter.com/medicinesforEU)